Non-myeloablative Lymphodepletion (NMA-LD) Regimen

Who we are

  • April 5, 2022
    Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors